-
Start Preamble
Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis Panel; Cancer Target Discovery and Development Network.
Date: October 18-19, 2012.
Time: 6 p.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Road, Bethesda, MD 20852.
Contact Person: Adriana Stoica, Ph.D., Scientific Review Officer, Special Review & Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 6116 Executive Blvd., Suite 703, Room 7072 Bethesda, MD 20892-8329, 301-594-1408, Stoicaa2@mail.nih.gov.
Name of Committee: National Cancer Institute Special Emphasis Panel; Validation and Advanced Development of Emerging Technologies for Cancer Research.
Date: October 30, 2012.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant applications.Start Printed Page 56216
Place: National Institutes of Health, 6120 Executive Boulevard, Room 511, Rockville, MD 20852.
Contact Person: Thomas A. Winters, Ph.D., Scientific Review Officer, Special Review & Logistics Branch, Division of Extramural Activities, 6116 Executive Boulevard, Room 8146, National Cancer Institute, NIH, Bethesda, MD 20892-8329, 301-594-1566, twinters@mail.nih.gov.
Name of Committee: National Cancer Institute Special Emphasis Panel; Quantitative Imaging for Evaluation of Responses to Cancer Therapies.
Date: October 31, 2012.
Time: 10 a.m. to 3 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6116 Executive Boulevard, Room 611, Rockville, MD 20852, (Telephone Conference Call).
Contact Person: Gerald G. Lovinger, Ph.D., Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 6116 Executive Boulevard, Room 8101 Bethesda, MD 20892-8329 301/496-7987 lovingeg@mail.nih.gov.
Name of Committee: National Cancer Institute Special Emphasis Panel; Cancer Diagnostic and Therapeutic Agents Enabled by Nanotechnology.
Date: November 27, 2012.
Time: 9 a.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6120 Executive Boulevard, Room J, Rockville, MD 20852, (Telephone Conference Call).
Contact Person: Savvas C. Makrides, Ph.D., Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 6116 Executive Boulevard., Room 8050A Bethesda, MD 20892, 301-496-7421 makridessc@mail.nih.gov.
Information is also available on the Institute's/Center's home page: http://deainfo.nci.nih.gov/advisory/sep/sep.htm,, where an agenda and any additional information for the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)
Start SignatureDated: September 6, 2012.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2012-22384 Filed 9-11-12; 8:45 am]
BILLING CODE 4140-01-P
Document Information
- Comments Received:
- 0 Comments
- Effective Date:
- 10/18/2012
- Published:
- 09/12/2012
- Department:
- National Institutes of Health
- Entry Type:
- Notice
- Document Number:
- 2012-22384
- Dates:
- October 18-19, 2012.
- Pages:
- 56215-56216 (2 pages)
- PDF File:
- 2012-22384.pdf
- Supporting Documents:
- » License Agreements; Start-Up Exclusive Evaluation Option: Activators of Human Pyruvate Kinase to Treat Cancer
- » Meetings: Eunice Kennedy Shriver National Institute of Child Health and Human Development
- » Meetings: National Institute of Nursing Research
- » Meetings: National Institute of Allergy and Infectious Diseases
- » Meetings: National Eye Institute
- » Meetings: Eunice Kennedy Shriver National Institute of Child Health and Human Development
- » Meetings: Center for Scientific Review
- » Meetings: Center for Scientific Review
- » Meetings: National Institute of Environmental Health Sciences
- » Meetings: National Human Genome Research Institute